Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.86 million versus the consensus estimate of $6.49 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.